MDXG vs ORGO
MDXG: MiMedx is a regenerative medicine company specializing in placental tissue-based therapies for advanced wound care and surgical applications. ORGO: A regenerative medicine company providing advanced wound care and surgical tissue-engineered products to improve healing outcomes in patients with chronic and acute wounds.
Side-by-side fundamentals
| Metric | MDXG | ORGO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $4.62 | $1.28 | |
| Market cap | $673M | $165M | |
| P/E as of 2026-10-08 | 116.96 | n/a | |
| Net margin FY2025, SEC XBRL | +11.6% | +6.6% | MDXG higher |
| Gross margin | +82.6% | +76.0% | MDXG higher |
| Operating margin FY2025, SEC XBRL | +15.3% | +7.9% | MDXG higher |
| ROE FY2025, SEC XBRL | +18.9% | +12.3% | MDXG higher |
| ROA FY2025, SEC XBRL | +14.2% | +6.2% | MDXG higher |
| Debt / equity as of 2026-09-03 | 0.08 | 0.03 | ORGO lower |
| Revenue growth (YoY) as of 2026-09-03 | -2.4% | +12.2% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | +16.1% | +7.8% | MDXG higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.64 | 1.53 | |
| 1-year return as of 2026-10-08 close | -34.9% | -69.0% | MDXG higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.